Stymied on Nasdaq, Apple Tree’s Braeburn sinks another short putt with late-stage implant
Braeburn Pharmaceuticals is not out to revolutionize therapy for the neurological and psychiatric diseases it focuses on. The Princeton, NJ-based biotech has one approved product for an implant that is designed to meter out a steady dose of buprenorphine — a well known generic — over 6 months for opioid addiction. And now it’s in the process of teeing up a similar FDA application for another implant that could provide a 6-month dose of risperidone to schizophrenics after running a small Phase II/III study with 50 patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.